| Active, not recruiting | 2 | 160 | US | Eyp-1901, Aflibercept 2Mg/0.05Ml Inj,Oph, Eylea | EyePoint Pharmaceuticals, Inc. | Wet Age-related Macular Degeneration | 11/23 | 04/24 | | |
NCT05383209: Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR) |
|
|
| Recruiting | 2 | 105 | US | EYP-1901, Sham IVT | EyePoint Pharmaceuticals, Inc. | Nonproliferative Diabetic Retinopathy | 02/24 | 08/25 | | |
| Not yet recruiting | 2 | 25 | NA | EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph | EyePoint Pharmaceuticals, Inc. | Diabetic Macular Edema | 01/25 | 01/25 | | |